Compounds > es-285
Page last updated: 2024-11-12

es-285

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

spisulosine: from marine organism, Spisula polynyma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-deoxysphinganine : A bioactive sphingoid, sphinganine, in which the terminal hydroxy group has been replaced by a hydrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9925886
CHEMBL ID1835439
CHEBI ID67106
SCHEMBL ID5654343
MeSH IDM0452979

Synonyms (33)

Synonym
(2s,3r)-2-aminooctadecan-3-ol
1-deoxy-sphinganine
LMSP01080032
2s-amino-octadecan-3r-ol
spisulosine
chebi:67106 ,
CHEMBL1835439 ,
3-octadecanol, 2-amino-, (2s,3r)-
196497-48-0
1-deoxysphinganine (0)
(2s,3r)-2-amino-3-hydroxyoctadecane
1-deoxysphinganine
es-285
spisulosine [who-dd]
3-octadecanol, 2-amino-, (r-(r*,s*))-
spisulosine 285
ZX5D253CYY ,
(+)-spisulosine
es285
es 285
doxsa cpd
unii-zx5d253cyy
SCHEMBL5654343
(2s, 3r)-2-amino-3-octadecanol
YRYJJIXWWQLGGV-ZWKOTPCHSA-N
DTXSID30432931
AKOS030542137
1-deoxysphinganine, 1-deoxysphinganine (m18:0), powder
2s-amino-3r-octadecanol
Q27135623
bdbm50496601
HY-13626
CS-0007491

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Using this schedule, 128 mg/m(2) was considered safe and feasible."( Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Baird, RD; Clarke, PA; de las Heras, B; deBono, JS; Eskens, F; Judson, IR; Kaye, SB; Kitzen, J; López Lázaro, L; Planting, A; Reade, S; Reid, A; Verweij, J; Welsh, L; Workman, P, 2009)		0.59

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies indicated dose proportionality with high volume of distribution (median V(ss) at 256 mg/m(2) was 2,389 liters; range, 1,615-4,051 liters) and long elimination half life (median t(1/2) at 256 mg/m(2) was 28 h; range, 21-32 h)."( Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Baird, RD; Clarke, PA; de las Heras, B; deBono, JS; Eskens, F; Judson, IR; Kaye, SB; Kitzen, J; López Lázaro, L; Planting, A; Reade, S; Reid, A; Verweij, J; Welsh, L; Workman, P, 2009)		0.59

Dosage Studied

The compound is pharmaceutically formulated as a lyophilised product containing 25 or 50 mg ES-285 x HCl and 500 or 1000 mg 2-hydroxypropyl-beta-cyclodextrin. It requires reconstitution with sterile water for injection before intravenous administration.

ExcerptRelevanceReference
" The pharmaceutical development of ES-285 x HCl warranted the availability of an assay for the quantification and purity determination of ES-285 x HCl active pharmaceutical ingredient (API) and its pharmaceutical dosage form."( Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.
Beijnen, JH; den Brok, MW; Floriano, P; Manzanares, I; Miranda, E; Munt, S; Nuijen, B, 2003)		0.79
" The usefulness and necessity of the modified assay was demonstrated by analysis of plasma samples from a patient receiving a low dosage of the drug."( A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.
Beijnen, JH; López-Lázaro, L; Rosing, H; Schellens, JH; Stokvis, E, 2004)		0.54
"HCl per dosage unit for use in phase I clinical trials."( Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
Beijnen, JH; Den Brok, MW; Manada, C; Meijer, DM; Millán, E; Nuijen, B, )		0.34
" The compound is pharmaceutically formulated as a lyophilised product containing 25 or 50 mg ES-285 x HCl and 500 or 1000 mg 2-hydroxypropyl-beta-cyclodextrin per dosage unit and requires reconstitution with sterile water for injection before intravenous administration."( Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.
Beijnen, JH; Calvo, P; Den Brok, MW; García, JL; Manada, C; Miranda, E; Nuijen, B, 2006)		0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
sphingoidSphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.
amino alcoholAn alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Biosynthesis and turnover of 1-deoxy-sphingoid bases013

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sphingosine kinase 2Homo sapiens (human)IC50 (µMol)766.00000.35603.535210.0000AID1077890
Sphingosine kinase 1Homo sapiens (human)IC50 (µMol)7.10000.00081.30397.1000AID1077891
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
blood vessel developmentSphingosine kinase 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseSphingosine kinase 2Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine kinase 2Homo sapiens (human)
sphinganine-1-phosphate biosynthetic processSphingosine kinase 2Homo sapiens (human)
sphingosine metabolic processSphingosine kinase 2Homo sapiens (human)
brain developmentSphingosine kinase 2Homo sapiens (human)
cell population proliferationSphingosine kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSphingosine kinase 2Homo sapiens (human)
sphingolipid biosynthetic processSphingosine kinase 2Homo sapiens (human)
negative regulation of cell growthSphingosine kinase 2Homo sapiens (human)
positive regulation of interleukin-13 productionSphingosine kinase 2Homo sapiens (human)
positive regulation of interleukin-6 productionSphingosine kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionSphingosine kinase 2Homo sapiens (human)
positive regulation of mast cell activation involved in immune responseSphingosine kinase 2Homo sapiens (human)
positive regulation of apoptotic processSphingosine kinase 2Homo sapiens (human)
regulation of canonical NF-kappaB signal transductionSphingosine kinase 2Homo sapiens (human)
positive regulation of mast cell degranulationSphingosine kinase 2Homo sapiens (human)
transcription initiation-coupled chromatin remodelingSphingosine kinase 2Homo sapiens (human)
sphingosine biosynthetic processSphingosine kinase 2Homo sapiens (human)
positive regulation of protein kinase C signalingSphingosine kinase 2Homo sapiens (human)
positive regulation of calcium ion importSphingosine kinase 2Homo sapiens (human)
regulation of reactive oxygen species biosynthetic processSphingosine kinase 2Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSphingosine kinase 2Homo sapiens (human)
regulation of cytochrome-c oxidase activitySphingosine kinase 2Homo sapiens (human)
positive regulation of ceramide biosynthetic processSphingosine kinase 2Homo sapiens (human)
regulation of ATP biosynthetic processSphingosine kinase 2Homo sapiens (human)
phosphorylationSphingosine kinase 2Homo sapiens (human)
negative regulation of apoptotic processSphingosine kinase 1Homo sapiens (human)
positive regulation of fibroblast proliferationSphingosine kinase 1Homo sapiens (human)
blood vessel developmentSphingosine kinase 1Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwaySphingosine kinase 1Homo sapiens (human)
protein acetylationSphingosine kinase 1Homo sapiens (human)
sphingosine metabolic processSphingosine kinase 1Homo sapiens (human)
inflammatory responseSphingosine kinase 1Homo sapiens (human)
brain developmentSphingosine kinase 1Homo sapiens (human)
cell population proliferationSphingosine kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSphingosine kinase 1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySphingosine kinase 1Homo sapiens (human)
phosphorylationSphingosine kinase 1Homo sapiens (human)
calcium-mediated signalingSphingosine kinase 1Homo sapiens (human)
regulation of endocytosisSphingosine kinase 1Homo sapiens (human)
sphingolipid biosynthetic processSphingosine kinase 1Homo sapiens (human)
positive regulation of cell growthSphingosine kinase 1Homo sapiens (human)
positive regulation of cell migrationSphingosine kinase 1Homo sapiens (human)
positive regulation of protein ubiquitinationSphingosine kinase 1Homo sapiens (human)
regulation of interleukin-1 beta productionSphingosine kinase 1Homo sapiens (human)
positive regulation of interleukin-17 productionSphingosine kinase 1Homo sapiens (human)
response to tumor necrosis factorSphingosine kinase 1Homo sapiens (human)
intracellular signal transductionSphingosine kinase 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSphingosine kinase 1Homo sapiens (human)
negative regulation of apoptotic processSphingosine kinase 1Homo sapiens (human)
positive regulation of angiogenesisSphingosine kinase 1Homo sapiens (human)
positive regulation of mitotic nuclear divisionSphingosine kinase 1Homo sapiens (human)
positive regulation of mitotic cell cycleSphingosine kinase 1Homo sapiens (human)
positive regulation of smooth muscle contractionSphingosine kinase 1Homo sapiens (human)
sphingosine biosynthetic processSphingosine kinase 1Homo sapiens (human)
sphingoid catabolic processSphingosine kinase 1Homo sapiens (human)
regulation of phagocytosisSphingosine kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySphingosine kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideSphingosine kinase 1Homo sapiens (human)
DNA biosynthetic processSphingosine kinase 1Homo sapiens (human)
regulation of neuroinflammatory responseSphingosine kinase 1Homo sapiens (human)
negative regulation of ceramide biosynthetic processSphingosine kinase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeSphingosine kinase 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionSphingosine kinase 1Homo sapiens (human)
regulation of microglial cell activationSphingosine kinase 1Homo sapiens (human)
regulation of endosomal vesicle fusionSphingosine kinase 1Homo sapiens (human)
cellular response to growth factor stimulusSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
lipid kinase activitySphingosine kinase 2Homo sapiens (human)
protein bindingSphingosine kinase 2Homo sapiens (human)
ATP bindingSphingosine kinase 2Homo sapiens (human)
sphinganine kinase activitySphingosine kinase 2Homo sapiens (human)
D-erythro-sphingosine kinase activitySphingosine kinase 2Homo sapiens (human)
small GTPase bindingSphingosine kinase 2Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine kinase 2Homo sapiens (human)
histone bindingSphingosine kinase 2Homo sapiens (human)
magnesium ion bindingSphingosine kinase 1Homo sapiens (human)
lipid kinase activitySphingosine kinase 1Homo sapiens (human)
DNA bindingSphingosine kinase 1Homo sapiens (human)
protein bindingSphingosine kinase 1Homo sapiens (human)
calmodulin bindingSphingosine kinase 1Homo sapiens (human)
ATP bindingSphingosine kinase 1Homo sapiens (human)
lipid bindingSphingosine kinase 1Homo sapiens (human)
sphinganine kinase activitySphingosine kinase 1Homo sapiens (human)
acetyltransferase activitySphingosine kinase 1Homo sapiens (human)
D-erythro-sphingosine kinase activitySphingosine kinase 1Homo sapiens (human)
sphingosine-1-phosphate receptor activitySphingosine kinase 1Homo sapiens (human)
protein phosphatase 2A bindingSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusSphingosine kinase 2Homo sapiens (human)
nucleoplasmSphingosine kinase 2Homo sapiens (human)
cytoplasmSphingosine kinase 2Homo sapiens (human)
mitochondrionSphingosine kinase 2Homo sapiens (human)
mitochondrial inner membraneSphingosine kinase 2Homo sapiens (human)
lysosomal membraneSphingosine kinase 2Homo sapiens (human)
endoplasmic reticulumSphingosine kinase 2Homo sapiens (human)
cytosolSphingosine kinase 2Homo sapiens (human)
membraneSphingosine kinase 2Homo sapiens (human)
nucleosomeSphingosine kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine kinase 2Homo sapiens (human)
membraneSphingosine kinase 2Homo sapiens (human)
cytoplasmSphingosine kinase 2Homo sapiens (human)
presynapseSphingosine kinase 1Homo sapiens (human)
nucleusSphingosine kinase 1Homo sapiens (human)
nucleoplasmSphingosine kinase 1Homo sapiens (human)
cytoplasmSphingosine kinase 1Homo sapiens (human)
cytosolSphingosine kinase 1Homo sapiens (human)
plasma membraneSphingosine kinase 1Homo sapiens (human)
clathrin-coated pitSphingosine kinase 1Homo sapiens (human)
endocytic vesicleSphingosine kinase 1Homo sapiens (human)
early endosome membraneSphingosine kinase 1Homo sapiens (human)
presynapseSphingosine kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleSphingosine kinase 1Homo sapiens (human)
membraneSphingosine kinase 1Homo sapiens (human)
cytoplasmSphingosine kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1204011Inhibition of human Casein kinase 1 alpha 1 assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204016Inhibition of human Casein kinase 1 gamma 2 assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204013Inhibition of human Casein kinase 1 delta assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688593Induction of autophagy in human DLD-1 cells assessed as reduction in cell viability at 7.5 uM incubated for 24 hrs in presence of Bafilomycin-A1 by crystal violet staining based phase contrast microscopic analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1688576Induction of apoptosis in human DLD-1 cells assessed as late apoptotic cells at 7.5 uM incubated for 18 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 5.7 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1077890Inhibition of purified SK2 (unknown origin) using sphingosine and [gamma-32P]ATP as substrate after 30 mins2013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1204010Antiproliferative activity against human WiDr cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204014Inhibition of human Casein kinase 1 epsilon assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204009Antiproliferative activity against human T47D cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688560Cytotoxicity against human HL-60 cell2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1204017Inhibition of human Casein kinase 1 gamma 3 assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688556Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1688578Induction of apoptosis in human DLD-1 cells assessed as increase in PARP cleavage at 5 to 7.5 uM by Western blot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1204015Inhibition of human Casein kinase 1 gamma 1 assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204008Antiproliferative activity against human SW1573 cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204006Antiproliferative activity against human HBL100 cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688575Induction of apoptosis in human DLD-1 cells assessed as early apoptotic cells at 7.5 uM incubated for 18 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 4.95 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1077891Inhibition of recombinant SK1 (unknown origin) using sphingosine and [gamma-32P]ATP as substrate after 30 mins2013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1204012Inhibition of human Casein kinase 1 alpha 1-like assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1204019Inhibition of human Casein kinase 2 alpha prime polypeptide assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688577Induction of apoptosis in human DLD-1 cells assessed as necrotic cells at 7.5 uM incubated for 18 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 4.1 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1077878Inhibition of DNA synthesis in human PAMSC cells assessed as [3H]-thymidine incorporation into DNA at 100 nM to 1 uM after 24 hrs2013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1204007Antiproliferative activity against human HeLa cells after 48 hrs incubation by SRB assay2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
AID1688558Cytotoxicity against human KB cell2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1077895Decrease of SK1 expression in human PAMSC cells at 10 uM after 24 hrs by Western blot analysis2013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1077896Decrease of SK1 expression in human PAMSC cells at 10 uM after 24 hrs by Western blot analysis in presence of proteasomal inhibitor MG1322013MedChemComm, , Volume: 4, Issue:10
Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.
AID1688557Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1688574Induction of apoptosis in human DLD-1 cells assessed as viable cells at 7.5 uM incubated for 18 hrs by Annexin V-FITC and propidium iodide staining based flow cytometry analysis (Rvb = 85.2 %)2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1688559Cytotoxicity against human HCT-116 cell2020European journal of medicinal chemistry, Feb-15, Volume: 188New Spisulosine Derivative promotes robust autophagic response to cancer cells.
AID1204018Inhibition of human Casein kinase 2 alpha 1 polypeptide assessed as residual activity at 10 uM relative to control2015European journal of medicinal chemistry, , Volume: 96Synthesis and identification of unprecedented selective inhibitors of CK1ε.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (33.33)29.6817
2010's19 (57.58)24.3611
2020's3 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.00 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.67 (0.95)

This Compound (22.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (14.71%)5.53%
Reviews2 (5.88%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other26 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		7.6152alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		6.3242L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sulfamic acid
sulfamic acid: standard in alkalimetry; RN given refers to parent cpd; structure. sulfamic acid : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.		2.0610sulfamic acids
phenylisothiocyanate
phenylisothiocyanate: structure. phenyl isothiocyanate : An isothiocyanate having a phenyl group attached to the nitrogen; used for amino acid sequencing in the Edman degradation.		7.0110isothiocyanateallergen;
reagent
phenylpropanolamine
Phenylpropanolamine: A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.. phenylpropanolamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group. A decongestant and appetite suppressant, it is commonly used in prescription and over-the-counter cough and cold preparations.. (-)-norephedrine : An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1R,2S-stereoisomer). It is a plant alkaloid.		2.0110amphetamines;
phenethylamine alkaloid		plant metabolite
dansyl chloride
dansyl chloride: RN given refers to unlabeled cpd		7.0110aminonaphthalene;
sulfonic acid derivative
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.2510delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
alkenes
[no description available]		2.0610
etoposide
[no description available]		2.1110beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
mephentermine
sphinganine : A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration.		2.11102-aminooctadecane-1,3-diolEC 2.7.11.13 (protein kinase C) inhibitor;
human metabolite;
mouse metabolite
phytosphingosine
phytosphingosine: differ with an additional hydroxyl at C-4 & no double bond between C-4 & C-5		2.0810amino alcohol;
sphingoid;
triol		mouse metabolite;
Saccharomyces cerevisiae metabolite
alaninal
[no description available]		2.0810
7-ethyl-7-hydroxy-10h-1,3-dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7h,12h)-dione
7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione: an antineoplastic agent that inhibits survivin, Mcl-1, and cIAP2; structure in first source		2.2510
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.0310cyclodextrin
safingol
safingol: RN given refers to the (R-(R*,S*))-isomer		2.0110amino alcohol
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		8.45132sphing-4-eninehuman metabolite;
mouse metabolite
1-oleoyl-2-acetylglycerol
[no description available]		2.03101,2-diglyceride
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
[no description available]		2.0810organochlorine compound
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.0310
dihydroceramide
dihydroceramide: lacks the 4-5 trans double bond of the sphingosine moiety of ceramides; structure in first source. N-acylsphinganine : A ceramide consisting of sphinganine in which one of the amino hydrogens is substituted by a fatty acyl group.. dihydroceramide : An N-acylsphingoid obtained by formal condensation of the carboxy group of any fatty acid with the amino group of any dihydrosphingoid base.		2.0810
kahalalide f
kahalalide F: a cyclodepsipeptide toxin; isolated from a mollusk, Elysia rubefescens; exhibits antitumoral activity against cell lines of colon cancer and prostatic cancer; structure given in first source		8.1310
pf-543
PF-543: Sphingosine Kinase 1 Selective Inhibitor; structure in first source		2.0810sulfonamide
rome
Rome: The capital city of Italy.. (2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol : A 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol that has R-configuration. It is a sphingosine kinase-2 inhibitor.		2.08102-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-olEC 2.7.1.91 (sphingosine kinase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		05.7454
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.7454
Autoimmune Diabetes
[description not available]		02.110
Diabetes Mellitus, Adult-Onset
[description not available]		02.5220
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.110
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.5220
Amino Acid Metabolism Disorders, Inborn
[description not available]		02.1110
Fatty Liver, Nonalcoholic
[description not available]		03.0310
Peripheral Nerve Diseases
[description not available]		03.0310
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		03.0310
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		03.0310
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		03.0310
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		02.1310
Acroosteolysis, Giaccai Type
[description not available]		07.9774
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		02.1310
Hereditary Sensory and Autonomic Neuropathies
A group of inherited disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and clinically by loss of sensation and autonomic dysfunction. There are five subtypes. Type I features autosomal dominant inheritance and distal sensory involvement. Type II is characterized by autosomal inheritance and distal and proximal sensory loss. Type III is DYSAUTONOMIA, FAMILIAL. Type IV features insensitivity to pain, heat intolerance, and mental deficiency. Type V is characterized by a selective loss of pain with intact light touch and vibratory sensation. (From Joynt, Clinical Neurology, 1995, Ch51, pp142-4)		07.9774
Lassitude
[description not available]		03.4311
Emesis
[description not available]		03.4311
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		03.4311
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.4311
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.4311
Sterility, Male
[description not available]		07.4944
Infertility, Male
The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.		07.4944
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.9340
Cancer of Prostate
[description not available]		02.0410
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0410